ARCHIVES

NCI Director Says Research Budget Cuts Result in Untold “Missed Opportunities,” Provides List of Program Reductions.

This article is from The Cancer Letter archive.

Vol. 33 No. 09 | March 9, 2007

Download PDF Visit The Full Archive

Related Articles

Austria Has highest Cancer Rate, Little NCI Support

June 17, 1977

Taxol Approved By FDA For Ovarian Cancer; Bristol Sets Price Tier In Line With Platinum

January 8, 1993

Gleevec Improves Survival Of CML In Accelerated Phase

December 27, 2002

Bad News for EPO Products Brings FDA Scrutiny, Payment Curbs. FDA Issues Alert to Doctors.

February 23, 2007

TGen’s Trent To Lead Van Andel Institute

February 13, 2009

In Brief: Lasagna Committee Report Finalized; Robinson Replaces Schmidt On MSK Boards

July 13, 1990